• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Surface Oncology Inc. (Amendment)

    1/31/23 8:57:04 AM ET
    $SURF
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SURF alert in real time by email
    SC 13G/A 1 tm234424d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Rule 13d-102)

     

    Information Statement Pursuant to Rules 13d-1 and 13d-2
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*

     

      sURFACE ONCOLOGY, Inc.  

    (Name of Issuer)

     

      Common Stock, $0.0001  

    (Title of Class of Securities)

     

      86877M209  

    (CUSIP Number)

     

      December 31, 2022  

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this schedule is filed:

     

    ¨ Rule 13d-1(b)

     

    ¨ Rule 13d-1(c)

     

    x Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  

     

    Atlas Venture Fund IX, L.P.  


    2.

    (a)                  ¨  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  

    (b)                  ¨  

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH  
      5.  SOLE VOTING POWER
       
      6.  SHARED VOTING POWER
    2,945,453  
      7.  SOLE DISPOSITIVE POWER
       
      8.  SHARED DISPOSITIVE POWER
    2,945,453  
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,945,453  

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES               ¨ 
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%  

    12.

    TYPE OF REPORTING PERSON*

    PN  

           

     

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  

     

    Atlas Venture Associates IX, L.P.


    2.

    (a)                  ¨  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  

    (b)                  ¨  

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH  
      5.  SOLE VOTING POWER
       
      6.  SHARED VOTING POWER
    2,945,453  
      7.  SOLE DISPOSITIVE POWER
       
      8.  SHARED DISPOSITIVE POWER
    2,945,453  
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,945,453  

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES               ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%  

    12.

    TYPE OF REPORTING PERSON*

    PN  

           

     

     

     

     

    1.

    NAME OF REPORTING PERSON

    S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON  

     

    Atlas Venture Associates IX, LLC


    2.

    (a)                  ¨  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*  

    (b)                  ¨  

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware  

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH  
      5.  SOLE VOTING POWER
       
      6.  SHARED VOTING POWER
    2,945,453  
      7.  SOLE DISPOSITIVE POWER
       
      8.  SHARED DISPOSITIVE POWER
    2,945,453  
    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    2,945,453  

    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES               ¨
    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    4.87%  

    12.

    TYPE OF REPORTING PERSON*

    OO  

           

     

     

     

    Item 1(a).Name of Issuer

     

    The name of the issuer to which this filing on Schedule 13G relates is Surface Oncology, Inc. (the “Company”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices

     

    The principal executive offices of the Company are located at 50 Hampshire Street, 8th Floor Cambridge, MA 02139.

     

    Item 2(a).Name of Person Filing

     

    This Statement is being filed on behalf of Atlas Venture Fund IX, L.P. ("Atlas IX"), Atlas Venture Associates IX, L.P. ("AVA IX LP"), the sole general partner of Atlas IX, and Atlas Venture Associates IX, LLC ("AVA IX LLC"), the sole general partner of AVA IX LP.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence

     

    The principal business address of each of Atlas IX, AVA IX LP, and AVA IX LLC is 56 Wareham Street, 3rd Flr, Boston, MA 02118.

     

    Item 2(c).Citizenship

     

    Each of Atlas IX, AVA IX LP and AVA IX LLC is organized under the laws of Delaware.

     

    Item 2(d).Title of Class of Securities

     

    The class of equity securities of the Company to which this filing on Schedule 13G relates is Common Stock, par value $0.0001 (“Common Stock”).

     

    Item 2(e).CUSIP Number

     

    The CUSIP number of the Company’s Common Stock is 86877M209.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable.

     

    (a)¨  Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)¨  Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 73c).
    (c)¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)¨ An investment adviser in accordance with §13d-1(b)(1)(ii)(E).
    (f)¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)¨ Group, in accordance with §240.13d-1(b)(1)(ii)(J).

     

    ¨If this statement is filed pursuant to §240.13d-1(c), check this box.

     

     

     

    Item 4.Ownership

     

    Item 4(a).Amount beneficially owned

     

    As of the close of business on December 31, 2022, Atlas IX is the record holder of 2,945,453 shares of Common Stock (the "Atlas IX Shares"). AVA IX LP is the sole general partner of Atlas IX. AVA IX LLC is the sole general partner of AVA IX LP. No person other than the respective owner referred to herein of the Atlas IX Shares is known to have the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of such Atlas IX Shares. Each of Atlas IX, AVA IX LP, and AVA IX LLC disclaim beneficial ownership of the Atlas IX Shares except for such shares, if any, such person holds of record.

     

    Item 4(b).Percent of Class

     

    As of the close of business on December 31, 2022, Atlas IX was the beneficial owner of 4.87% of the Common Stock, based on 60,542,261 shares outstanding as listed in the Company’s 10-Q filed on November 2, 2022.

     

    Item 4(c).Number of shares as to which the person has:

     

       Number of Shares of Common Stock 
    Reporting Person  (i)   (ii)   (iii)   (iv) 
    Atlas IX   -0-    2,945,453    -0-    2,945,453 
    AVA IX LP   -0-    2,945,453    -0-    2,945,453 
    AVA IX Inc.   -0-    2,945,453    -0-    2,945,453 

     

    (i)Sole power to vote or direct the vote
    (ii)Shared power to vote or to direct the vote
    (iii)Sole power to dispose or to direct the disposition of
    (iv)Shared power to dispose or to direct the disposition of

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    Each Filing Person has ceased to own beneficially more than 5% of the outstanding Common Stock of the Company.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

    Item 7.Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

     

    Not Applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not Applicable. The Filing Persons expressly disclaim membership in a "group" as used in Rule 13d-5(b)(1).

     

    Item 9.Notice of Dissolution of Group

     

    Not Applicable.

     

    Item 10.Certification

     

    Not Applicable. This statement on Schedule 13G is not filed pursuant to Rule 13d-1(b) or 13(d)-1(c).

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: January 31, 2023

     

      ATLAS VENTURE FUND IX, L.P.
       
      By: Atlas Venture Associates IX, L.P.,
      its general partner
       
      By: Atlas Venture Associates IX, LLC,
      its general partner
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary
       
      ATLAS VENTURE ASSOCIATES IX, L.P.
       
      By: Atlas Venture Associates IX, LLC,
      its general partner
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary
       
      ATLAS VENTURE ASSOCIATES IX, LLC
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary

     

     

     

    Exhibit A

     

    Joint Filing Agreement

     

    The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained herein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

     

    Dated: January 31, 2023

     

      ATLAS VENTURE FUND IX, L.P.
       
      By: Atlas Venture Associates IX, L.P.,
      its general partner
       
      By: Atlas Venture Associates IX, LLC,
      its general partner
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary
       
      ATLAS VENTURE ASSOCIATES IX, L.P.
       
      By: Atlas Venture Associates IX, LLC,
      its general partner
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary
       
      ATLAS VENTURE ASSOCIATES IX, LLC
       
      By: /s/ Frank Castellucci
        Name: Frank Castellucci
        Title: Secretary

     

     

     

    Get the next $SURF alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SURF

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SURF
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Surface Oncology Announces ISS and Glass Lewis Both Recommend Stockholders Vote "FOR" the Proposed Merger with Coherus BioSciences

      CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) ("Surface"), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that both Institutional Shareholder Services ("ISS") and Glass, Lewis & Co. ("Glass Lewis") have recommended Surface stockholders vote "FOR" the adoption of Surface's merger agreement (the "merger agreement") with Coherus BioSciences, Inc. (NASDAQ:CHRS) ("Coherus"). ISS and Glass Lewis are the leading independent, third-party proxy advisors to thousands of institutional investors and pension funds. Both advisory firms believe the proposed adoption of

      8/31/23 4:01:00 PM ET
      $CHRS
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

      CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. "We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards completing our planned merger with Coherus BioSciences," said Rob Ross, M.D., chief executive officer of Surface. "To truly realize the potential of SRF388 and SRF114, it is essential that these mole

      8/2/23 7:00:00 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Lifshitz Law PLLC Announces Investigations of SURF, NETI, NEX, and PTEN

      NEW YORK, June 24, 2023 (GLOBE NEWSWIRE) -- Surface Oncology, Inc. (NASDAQ:SURF) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of SURF to Coherus BioSciences, Inc. Under the terms of the agreement, SURF shareholders will receive Cohreus BioSciences, Inc. common stock at a price of $5.2831 per share for each share of SURF common stock owned. SURF shareholders will also receive certain CVRs as part of the agreement. If you are a SURF investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail

      6/24/23 8:11:00 PM ET
      $NETI
      $NEX
      $PTEN
      $SURF
      Marine Transportation
      Consumer Discretionary
      Oilfield Services/Equipment
      Energy

    $SURF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Surface Oncology with a new price target

      BTIG Research initiated coverage of Surface Oncology with a rating of Buy and set a new price target of $17.00

      5/18/21 6:55:59 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SURF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Surface Oncology Inc.

      SC 13G - Surface Oncology, Inc. (0001718108) (Subject)

      7/20/23 8:00:28 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Surface Oncology Inc. (Amendment)

      SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

      2/13/23 2:08:49 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Surface Oncology Inc. (Amendment)

      SC 13G/A - Surface Oncology, Inc. (0001718108) (Subject)

      2/10/23 2:08:51 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SURF
    Financials

    Live finance-specific insights

    See more
    • Surface Oncology Reports Financial Results and Corporate Highlights for Second Quarter 2023

      CAMBRIDGE, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today reported financial results and corporate highlights for the second quarter 2023. "We are pleased with the progress we have made over the past several months which includes the advancement of the SRF388 and SRF114 clinical trials and the significant efforts we have undertaken towards completing our planned merger with Coherus BioSciences," said Rob Ross, M.D., chief executive officer of Surface. "To truly realize the potential of SRF388 and SRF114, it is essential that these mole

      8/2/23 7:00:00 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Acquire Surface Oncology

      – Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs– – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and affir

      6/16/23 7:01:00 AM ET
      $CHRS
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Coherus to Acquire Surface Oncology

      – Surface acquisition and potential toripalimab approval will transform Coherus into an I-O company with multiple next-generation immunotherapies in clinical development funded by growing revenues – – Acquisition significantly advances Coherus' I-O pipeline with anti-IL-27 and anti-CCR8 clinical programs–       – Stock for stock transaction valued at up to $65 million, an approximate three-fold premium over Surface's anticipated net cash of $20 to $25 million at closing; Surface shareholders will also receive CVRs based on potential future payments for previously partnered assets and for potential ex-US licensing – – Coherus projects $48 - 53 million of net product revenue in 2Q 2023, and

      6/16/23 7:01:00 AM ET
      $CHRS
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SURF
    Leadership Updates

    Live Leadership Updates

    See more
    • Surface Oncology Appoints Carsten Brunn to Board of Directors

      CAMBRIDGE, Mass., June 29, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Carsten Brunn, Ph.D., will join the company's board of directors. Dr. Brunn brings more than 25 years of senior leadership experience spanning multiple biotech and pharmaceutical companies around the globe. "I am thrilled to welcome Carsten to the Surface Oncology board," said Rob Ross, M.D., chief executive officer at Surface. "Carsten is an accomplished biopharma executive with significant experience driving innovation and his counsel will be invaluable as we ad

      6/29/22 7:00:00 AM ET
      $SELB
      $SURF
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Surface Oncology Appoints Theresa Boni as General Counsel

      CAMBRIDGE, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointment of Theresa Boni, J.D., as general counsel and senior vice president, legal. Ms. Boni has more than 20 years of legal experience spanning the biopharmaceutical and medical device industries. "Teri is an impressive leader who brings deep legal and business acumen combined with a passion for improving the lives of patients, and we are delighted to welcome her to Surface," said Rob Ross, M.D., chief executive officer. "Her extensive life-science experience

      3/15/22 7:30:00 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Surface Oncology Appoints Denice Torres as Chair of the Board of Directors

      Biopharma veteran Ben Hickey appointed to Board of Directors Lisa McGrath promoted to chief people officer; Shannon Devens promoted to senior vice president, development operations CAMBRIDGE, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced the appointments of Denice Torres to chair of the board of directors and Ben Hickey to board director. In conjunction with the board appointments, Jeff Goater will transition to board director. The company also announced internal promotions of key senior executives, naming Lisa McGrath chie

      12/15/21 7:05:00 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SURF
    SEC Filings

    See more
    • SEC Form 15-12G filed by Surface Oncology Inc.

      15-12G - Surface Oncology, Inc. (0001718108) (Filer)

      9/15/23 7:27:26 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Surface Oncology Inc.

      EFFECT - Surface Oncology, Inc. (0001718108) (Filer)

      9/13/23 12:15:07 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form EFFECT filed by Surface Oncology Inc.

      EFFECT - Surface Oncology, Inc. (0001718108) (Filer)

      9/13/23 12:15:05 AM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SURF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Adams Chandra returned 23,884 shares to the company, closing all direct ownership in the company

      4 - Surface Oncology, Inc. (0001718108) (Issuer)

      9/8/23 4:00:31 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Sigal Charles Elliott returned 45,453 shares to the company

      4 - Surface Oncology, Inc. (0001718108) (Issuer)

      9/8/23 4:00:37 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Palombella Vito J. returned 87,212 shares to the company, closing all direct ownership in the company

      4 - Surface Oncology, Inc. (0001718108) (Issuer)

      9/8/23 4:00:25 PM ET
      $SURF
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care